Advertisement
Advertisement
FEMY
Femasys Inc. Common Stock
1.37
USDSponsored
+0.06
+4.58%
Nov 06, 15:59 UTC -5
Closed
After-Market
1.38
0.00
+0.36%
Femasys Inc. Common Stock (FEMY) Earnings
FEMY Earnings Reports
Positive Surprise Ratio
FEMY beat 10 of 20 last estimates.
50%
Next Report
Next Week
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
$631.89K
/-$0.52
Implied change from Q2 26 (Revenue/ EPS)
+90.33%
/-66.45%
Implied change from Q3 25 (Revenue/ EPS)
-13.32%
/-74.00%
Femasys Inc. Common Stock earnings per share and revenue
On Aug 14, 2026, FEMY reported earnings of -1.55 USD per share (EPS) for Q2 26, missing the estimate of -1.32 USD, resulting in a -16.89% surprise. Revenue reached 332.00 thousand, compared to an expected 745.28 thousand, with a -55.45% difference. The market reacted with a -5.68% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.52 USD, with revenue projected to reach 631.89 thousand USD, implying an decrease of -66.45% EPS, and increase of 90.33% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Femasys Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Femasys Inc. Common Stock reported EPS of -$1.55, missing estimates by -16.89%, and revenue of $332.00K, -55.45% below expectations.
How did the market react to Femasys Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -5.68%, changed from $2.29 before the earnings release to $2.16 the day after.
When is Femasys Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Femasys Inc. Common Stock's next earnings report?
Based on 3
analysts, Femasys Inc. Common Stock is expected to report EPS of -$0.52 and revenue of $631.89K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.